Pearl River Capital’s AbbVie ABBV Stock Holding History

Pearl River Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,120	Closed	-$568K	–	403
2024 Q1	$568K	Sell	3,120 -43,375	-93%	-$7.48M	0.09%	284
2023 Q4	$7.21M	Buy	+46,495	New	+$6.78M	1.15%	9
2023 Q3	–	Sell	-29,576	Closed	-$3.98M	–	479
2023 Q2	$3.98M	Buy	+29,576	New	+$4.34M	0.64%	31
2022 Q3	–	Sell	-27,896	Closed	-$4.27M	–	443
2022 Q2	$4.27M	Buy	+27,896	New	+$4.26M	1%	8
2021 Q3	–	Sell	-18,460	Closed	-$2.08M	–	386
2021 Q2	$2.08M	Buy	+18,460	New	+$2.08M	0.57%	37
2020 Q4	–	Sell	-26,764	Closed	-$2.34M	–	348
2020 Q3	$2.34M	Buy	+26,764	New	+$2.52M	0.98%	12
2019 Q1	–	Sell	-900	Closed	-$83K	–	342
2018 Q4	$83K	Buy	+900	New	+$79.1K	0.38%	67

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Pearl River Capital's ABBV Position: Q2 2024 in Review

Pearl River Capital sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 3,120 shares — an estimated $568K sold.

Pearl River Capital first reported a position in ABBV in Q4 2018 and held it in 7 quarters. The position peaked at $7.21M in Q4 2023. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Pearl River Capital reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 3,120 AbbVie shares in Q2 2024, an estimated $568K.
Pearl River Capital first reported a position in AbbVie in Q4 2018 and held it in 7 quarters.
Pearl River Capital's AbbVie position peaked at $7.21M in Q4 2023.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.